Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis

Méndez-Sánchez, Nahúm; Cerda-Reyes, Eira; Higuera-de-la-Tijera, Fátima; Salas-García, Ana K.; Cabrera-Palma, Samantha; Cabrera-Álvarez, Guillermo; Cortéz-Hernández, Carlos Alejandro; Pérez-Arredondo, Luis Alberto; Purón-González, Emma; Coronado-Alejandro, Edgar Ulises; Panduro, Arturo; Rodríguez-Hernández, Heriberto; Cruz-Ramón, Vania; Valencia-Rodríguez, Alejandro; Qi, Xingshun; Hamdan‐Pérez, Nashla; Aguilar-Olivos, Nancy E.; Barranco-Fragoso, Beatriz; Ramírez-Pérez, Oscar; Vera-Barajas, Alfonso

doi:10.12688/f1000research.21918.1

Cited by 32 publications

(23 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Männistö et al revealed a significant association between serum LDL and VLDL subclasses with inflammation and liver damage. Méndez-Sánchez et al also showed that steatohepatitis and liver fibrosis are more likely to have high VLDL and LDL serum concentration than simple steatosis (24). Similarly, we investigated the relationship of VLDL cholesterol level to liver fibrosis.…”

Section: Discussionmentioning

confidence: 79%

See 1 more Smart Citation

The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients

Ganjooei

Jamialahmadi

Nematy

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background and Aims: Obesity is one of the major health problems worldwide. Morbid obesity (body mass index >40 kg/m2 or over 35 with a comorbidity) is associated, apart from other diseases, with an increased risk of non-alcoholic fatty liver disease (NAFLD). Moreover, dyslipidemia is an important comorbidity that is frequently found in NAFLD patients. The aim of this study was to analyze whether serum lipids in morbidly obese patients are associated with the spectrum of NAFLD.Methods: Total serum cholesterol, LDL cholesterol, HDL cholesterol, non-HDL cholesterol, VLDL, and triglycerides were analyzed in 90 morbidly obese patients. The association of lipid profile parameters with histopathological, elastographic, and sonographic indices of NAFLD, non-alcoholic steatohepatitis (NASH), and liver fibrosis were explored.Results: The mean levels of serum total cholesterol, LDL-C, and non-HDL cholesterol in patients with positive histology for liver steatosis and NASH were significantly higher than those in patients with negative histology. None of the indices showed a strong association with NAFLD, NASH, or liver fibrosis after adjustment for potential confounders.Conclusion: A slight predictive value of lipid profile is not sufficiently enough to use solely as a non-invasive test in predicting NASH or liver fibrosis.

show abstract

Section: Discussionmentioning

confidence: 79%

“…Due to the high visceral fat distribution in Hispanic population, the risk of NAFLD deterioration will also be increased (23). Consequently, it could be a great development to find a non-invasive screening method for such a high-risk group to reduce more adverse complications (24).…”

Section: Discussionmentioning

confidence: 99%

The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients

Ganjooei

Jamialahmadi

Nematy

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Moreover, dyslipidemia is responsible for cardiovascular risk in NAFLD patients. 72 Hypertriglyceridemia was found to be highest in East Asians and non-Hispanic Whites and lowest in the African American population. 73 The prevalence of high low-density lipoprotein cholesterol was higher in Asian Indians, Filipinos, Japanese, and Vietnamese compared to non-Hispanic Whites.…”

Section: Metabolic Syndromementioning

confidence: 98%

Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally

Han

Tafesh

et al. 2020

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Globally, the rise in prevalence of obesity and metabolic syndrome as a whole has been linked to increased access to processed foods, such as refined sugars and saturated fats. Consequently, nonalcoholic fatty liver disease (NAFLD) is on the rise in both developed and developing nations. However, much is still unknown on the NAFLD phenotype with regards to the effect of ethnic diversity. Despite similarities in dietary habits, it appears that certain ethnicities are more protected against NAFLD than others. However, manifestations of the same genetic polymorphisms in different groups of people increase those individuals’ predisposition to NAFLD. Diets from different regions have been associated with a lower prevalence of NAFLD and have even been linked to regression of hepatic steatosis. Socioeconomic variations amongst different regions of the world also contribute to NAFLD prevalence and associated complications. Thus, a thorough understanding of ethnic variability in NAFLD is essential to tailoring treatment recommendations to patients of different backgrounds.

show abstract

“…Chronic consumption of “western” diet increases circulating levels of multiple toxins and bacterial products by altering gut flora and intestinal permeability in patients and in murine models, with subsequent intra-hepatic activation of hepatic immune cells, which, is a key phenomenon for the initiation of injury. In addition, this overnutrition and high-calorie diet induce insulin resistance, generating a dysfunctional adipose tissue (AT), leading to the breakdown of triglycerides (TGs) and consequently the formation of free fatty acids (FFAs) and glycerol ( 19 , 20 ). The increase in the circulating FFAs enhances their uptake by the liver leading to lipid accumulation ( 21 ).…”

Section: Introductionmentioning

confidence: 99%

Hepatic Dendritic Cells in the Development and Progression of Metabolic Steatohepatitis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Metabolic Associated Fatty liver disease (MAFLD) is a global health problem and represents the most common cause of chronic liver disease in the world. MAFLD spectrum goes from simple steatosis to cirrhosis, in between metabolic steatohepatitis with progressive fibrosis, which pathogenesis is not completely understood. Hence, the role of the immune system has become an important fact in the trigger of inflammatory cascades in metabolic steatohepatitis and in the activation of hepatic stellate cells (HSCs). Among, the more studied immune cells in the pathogenesis of MAFLD are macrophages, T cells, natural killer and dendritic cells. In particular, hepatic dendritic cells had recently attracted a special attention, with a dual role in the pathogenesis of MAFLD. These cells have the capacity to switch from a tolerant state to active state inducing an inflammatory cascade. Furthermore, these cells play a role in the lipid storage within the liver, having, thus providing a crucial nexus between inflammation and lipid metabolism. In this review, we will discuss the current knowledge on the dual role of dendritic cells in lipid accumulation, as wells as in the triggering of hepatic inflammation and hepatocytes cell death in metabolic steatohepatitis.

show abstract

Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis

Abstract: Nonalcoholic fatty liver disease (NAFLD) is a serious Background: worldwide health problem, with an estimated global prevalence of 24%

Cited by 32 publications

References 36 publications

The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients

The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients

Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally

Hepatic Dendritic Cells in the Development and Progression of Metabolic Steatohepatitis

Contact Info

Product

Resources

About